These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10822447)

  • 1. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease.
    Hock C; Heese K; Müller-Spahn F; Huber P; Riesen W; Nitsch RM; Otten U
    Neurology; 2000 May; 54(10):2009-11. PubMed ID: 10822447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression.
    Hock C; Heese K; Müller-Spahn F; Huber P; Riesen W; Nitsch RM; Otten U
    Mol Psychiatry; 2000 Sep; 5(5):510-3. PubMed ID: 11032384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.
    Blasko I; Lederer W; Oberbauer H; Walch T; Kemmler G; Hinterhuber H; Marksteiner J; Humpel C
    Dement Geriatr Cogn Disord; 2006; 21(1):9-15. PubMed ID: 16244482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties.
    Marksteiner J; Pirchl M; Ullrich C; Oberbauer H; Blasko I; Lederer W; Hinterhuber H; Humpel C
    Pharmacology; 2008; 82(3):214-20. PubMed ID: 18810245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid nerve growth factor levels in patients with Alzheimer's disease.
    Mashayekhi F; Salehin Z
    Ann Saudi Med; 2006; 26(4):278-82. PubMed ID: 16883086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
    Hock C; Golombowski S; Müller-Spahn F; Naser W; Beyreuther K; Mönning U; Schenk D; Vigo-Pelfrey C; Bush AM; Moir R; Tanzi RE; Growdon JH; Nitsch RM
    Eur Neurol; 1998; 39(2):111-8. PubMed ID: 9520072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF.
    Kahle PJ; Jakowec M; Teipel SJ; Hampel H; Petzinger GM; Di Monte DA; Silverberg GD; Möller HJ; Yesavage JA; Tinklenberg JR; Shooter EM; Murphy GM
    Neurology; 2000 Apr; 54(7):1498-504. PubMed ID: 10751266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
    Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.
    Buerger K; Zinkowski R; Teipel SJ; Arai H; DeBernardis J; Kerkman D; McCulloch C; Padberg F; Faltraco F; Goernitz A; Tapiola T; Rapoport SI; Pirttilä T; Möller HJ; Hampel H
    Am J Psychiatry; 2003 Feb; 160(2):376-9. PubMed ID: 12562590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
    Karami A; Eyjolfsdottir H; Vijayaraghavan S; Lind G; Almqvist P; Kadir A; Linderoth B; Andreasen N; Blennow K; Wall A; Westman E; Ferreira D; Kristoffersen Wiberg M; Wahlund LO; Seiger Å; Nordberg A; Wahlberg L; Darreh-Shori T; Eriksdotter M
    Alzheimers Dement; 2015 Nov; 11(11):1316-28. PubMed ID: 25676388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic marker.
    Jiao SS; Bu XL; Liu YH; Wang QH; Liu CH; Yao XQ; Zhou XF; Wang YJ
    Transl Psychiatry; 2015 Oct; 5(10):e650. PubMed ID: 26440538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor.
    Ferreira D; Westman E; Eyjolfsdottir H; Almqvist P; Lind G; Linderoth B; Seiger A; Blennow K; Karami A; Darreh-Shori T; Wiberg M; Simmons A; Wahlund LO; Wahlberg L; Eriksdotter M
    J Alzheimers Dis; 2015; 43(3):1059-72. PubMed ID: 25147108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
    Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
    Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medial temporal lobe atrophy increases the specificity of cerebrospinal fluid biomarkers in Alzheimer disease with minor cerebrovascular changes.
    Zhang Y; Londos E; Minthon L; Wattmo C; Blennow K; Liu HJ; Bronge L; Aspelin P; Wahlund LO
    Acta Radiol; 2009 Jul; 50(6):674-81. PubMed ID: 19455444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease].
    Schonknecht P; Pantel J; Werle E; Hartmann T; Essig M; Baudendistel K; Beyreuther K; Schroder J
    Fortschr Neurol Psychiatr; 2000 Oct; 68(10):439-46. PubMed ID: 11103680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?
    Kapaki E; Kilidireas K; Paraskevas GP; Michalopoulou M; Patsouris E
    J Neurol Neurosurg Psychiatry; 2001 Sep; 71(3):401-3. PubMed ID: 11511720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
    Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
    J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.